Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 261


Literature review of visual representation of the results of benefit-risk assessments of medicinal products.

Hallgreen CE, Mt-Isa S, Lieftucht A, Phillips LD, Hughes D, Talbot S, Asiimwe A, Downey G, Genov G, Hermann R, Noel R, Peters R, Micaleff A, Tzoulaki I, Ashby D; PROTECT Benefit-Risk group.

Pharmacoepidemiol Drug Saf. 2015 Nov 2. doi: 10.1002/pds.3880. [Epub ahead of print] Review.


Manifestation of West Nile Encephalitis in Infancy.

Appavu B, Ashby D, Condie J.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):e166-8. doi: 10.1093/jpids/piv072. Epub 2015 Oct 14. No abstract available.


Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions.

Pignatti F, Ashby D, Brass EP, Eichler HG, Frey P, Hillege HL, Hori A, Levitan B, Liberti L, Löfstedt RE, McAuslane N, Micaleff A, Noel RA, Postmus D, Renn O, Sabourin BJ, Salmonson T, Walker S.

Clin Pharmacol Ther. 2015 Nov;98(5):522-33. doi: 10.1002/cpt.203. Epub 2015 Sep 11. Review.


Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.

Abbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Nijher GM, Comninos AN, Peters D, Buckley A, Ratnasabapathy R, Prague JK, Salim R, Lavery SA, Bloom SR, Szigeti M, Ashby DA, Trew GH, Dhillo WS.

J Clin Endocrinol Metab. 2015 Sep;100(9):3322-31. doi: 10.1210/jc.2015-2332. Epub 2015 Jul 20.


A Bump on the Knee.

Khodaee M, Ashby D.

Am Fam Physician. 2015 Jul 15;92(2):149-50. No abstract available.


Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.

Alton EW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, Boyd AC, Brand J, Buchan R, Calcedo R, Carvelli P, Chan M, Cheng SH, Collie DD, Cunningham S, Davidson HE, Davies G, Davies JC, Davies LA, Dewar MH, Doherty A, Donovan J, Dwyer NS, Elgmati HI, Featherstone RF, Gavino J, Gea-Sorli S, Geddes DM, Gibson JS, Gill DR, Greening AP, Griesenbach U, Hansell DM, Harman K, Higgins TE, Hodges SL, Hyde SC, Hyndman L, Innes JA, Jacob J, Jones N, Keogh BF, Limberis MP, Lloyd-Evans P, Maclean AW, Manvell MC, McCormick D, McGovern M, McLachlan G, Meng C, Montero MA, Milligan H, Moyce LJ, Murray GD, Nicholson AG, Osadolor T, Parra-Leiton J, Porteous DJ, Pringle IA, Punch EK, Pytel KM, Quittner AL, Rivellini G, Saunders CJ, Scheule RK, Sheard S, Simmonds NJ, Smith K, Smith SN, Soussi N, Soussi S, Spearing EJ, Stevenson BJ, Sumner-Jones SG, Turkkila M, Ureta RP, Waller MD, Wasowicz MY, Wilson JM, Wolstenholme-Hogg P; UK Cystic Fibrosis Gene Therapy Consortium.

Lancet Respir Med. 2015 Sep;3(9):684-91. doi: 10.1016/S2213-2600(15)00245-3. Epub 2015 Jul 3.


Use of an uncensored primary outcome in a catheter design trial?

Ashby DR, Corbett RW.

Am J Kidney Dis. 2015 Jul;66(1):170. doi: 10.1053/j.ajkd.2015.03.037. Epub 2015 May 19. No abstract available.


Hepcidin-25 in diabetic chronic kidney disease is predictive for mortality and progression to end stage renal disease.

Wagner M, Ashby DR, Kurtz C, Alam A, Busbridge M, Raff U, Zimmermann J, Heuschmann PU, Wanner C, Schramm L.

PLoS One. 2015 Apr 20;10(4):e0123072. doi: 10.1371/journal.pone.0123072. eCollection 2015.


Prokinetics prescribing in paediatrics: evidence on cisapride, domperidone, and metoclopramide.

Mt-Isa S, Tomlin S, Sutcliffe A, Underwood M, Williamson P, Croft NM, Ashby D.

J Pediatr Gastroenterol Nutr. 2015 Apr;60(4):508-14. doi: 10.1097/MPG.0000000000000657.


A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment.

Waddingham E, Mt-Isa S, Nixon R, Ashby D.

Biom J. 2015 Jan 28. doi: 10.1002/bimj.201300254. [Epub ahead of print]


Ursodeoxycholic acid for cystic fibrosis-related liver disease.

Cheng K, Ashby D, Smyth RL.

Cochrane Database Syst Rev. 2014 Dec 15;12:CD000222. doi: 10.1002/14651858.CD000222.pub3. Review.


Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults.

Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, Zac-Varghese SE, MacDougall K, Preston T, Tedford C, Finlayson GS, Blundell JE, Bell JD, Thomas EL, Mt-Isa S, Ashby D, Gibson GR, Kolida S, Dhillo WS, Bloom SR, Morley W, Clegg S, Frost G.

Gut. 2015 Nov;64(11):1744-54. doi: 10.1136/gutjnl-2014-307913. Epub 2014 Dec 10.


Alternatives to arteriovenous fistulas.

Corbett RW, Ashby DR, Duncan ND.

BMJ. 2014 Dec 2;349:g7249. doi: 10.1136/bmj.g7249. No abstract available.


Stability of avoidance behaviour following repeated intermittent treatment with clozapine, olanzapine or D,L-govadine.

Ashby DM, Lapish CC, Phillips AG.

Behav Pharmacol. 2015 Feb;26(1-2):133-8. doi: 10.1097/FBP.0000000000000097.


Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology.

Hallgreen CE, van den Ham HA, Mt-Isa S, Ashworth S, Hermann R, Hobbiger S, Luciani D, Micaleff A, Thomson A, Wang N, van Staa TP, Downey G, Hirsch I, Hockley K, Juhaeri J, Metcalf M, Mwangi J, Nixon R, Peters R, Stoeckert I, Waddingham E, Tzoulaki I, Ashby D, Wise L.

Pharmacoepidemiol Drug Saf. 2014 Sep;23(9):974-83. doi: 10.1002/pds.3676. Epub 2014 Jul 5.


Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.

Jayasena CN, Abbara A, Comninos AN, Nijher GM, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Sridharan M, Mason AJ, Warwick J, Ashby D, Ghatei MA, Bloom SR, Carby A, Trew GH, Dhillo WS.

J Clin Invest. 2014 Aug;124(8):3667-77. doi: 10.1172/JCI75730. Epub 2014 Jul 18.


Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH).

Gordon AC, Mason AJ, Perkins GD, Ashby D, Brett SJ.

BMJ Open. 2014 Jul 3;4(7):e005866. doi: 10.1136/bmjopen-2014-005866.


Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.

Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, Sacerdote C, Ashby D, Vineis P, Tzoulaki I, Ioannidis JP.

Diabetes Care. 2014 Sep;37(9):2522-32. doi: 10.2337/dc14-0584. Epub 2014 Jun 4.


An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial.

Orme RM, Perkins GD, McAuley DF, Liu KD, Mason AJ, Morelli A, Singer M, Ashby D, Gordon AC.

Trials. 2014 Jun 2;15:199. doi: 10.1186/1745-6215-15-199.


Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.

Mt-Isa S, Hallgreen CE, Wang N, Callréus T, Genov G, Hirsch I, Hobbiger SF, Hockley KS, Luciani D, Phillips LD, Quartey G, Sarac SB, Stoeckert I, Tzoulaki I, Micaleff A, Ashby D; IMI-PROTECT benefit-risk participants.

Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):667-78. doi: 10.1002/pds.3636. Epub 2014 May 13. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk